03007cam a2200349 a 4500 EG-GiCUC 20250223032842.0 211104s2021 ua d f m 000 0 eng d EG-GiCUC eng EG-GiCUC eng Deposite Ph.D Cai01.11.20.Ph.D.2021.Mo.R Mohammed Said Hassan Rituximab versus azathioprine therapy in neuromyelitis optica spectrum disorder patients / Mohammed Said Hassan ; Supervised Sherif Hamdy , Nevin Moheildin , Ahmed Nemr عقار ريتوكسيماب مقابل عقار الأزاثيوبرين فى مرضى التهاب النخاع العصبى الطيفى البصرى Cairo : Mohammed Said Hassan , 2021 164 P . : charts ; 25cm Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Neuro Surgery Background: Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system characterized by severe attacks of optic neuritis and longitudinally extensive transverse myelitis. Recently, the demonstration of a pathogenic role for the anti{u2013}aquaporin 4 (AQP4) antibody in NMO has marked a major advance in the understanding o the disease Aim of work: The aim of this study was to report the results of rituximab treatment in NMO spectrum disorders (NMOSDs) Patients and Methods: This was a retrospective observational study conducted on 74 Egyptian patients with NMOSDs. The patients{u2018} data were recruited from patient records in multiple sclerosis (MS) clinics, Neurology Departments, El- Maady Military Hospital (records from 2005) and Cairo University hospitals (Kasr Al-Ainy MS Clinic) (records from 2013) including their full medical history, general and neurological examination, MRI brain and spinal cord results, and laboratory investigation including: immune assays and AQP- 4antibody testing as per MS and MS mimics sheet of Kasr Al-Ainy MS clinic.Results: The study included 74 Patients with NMOSD according to criteria of Wagnerchuck 2015. Both sero-positive and sero-negative anti-aquaporin-4 (AQP-4) antibodies patients were included in the study. The patients were divided into three groups: group 1 (RTX group) included 25 patient; group 2 (AZA group) included 32 patients, and group 3 (Switchers) included 17 patients. Conclusion: our findings suggest that RTX is more effective and safe than AZA in NMO-SD patients. Further studies with larger sample sizes and longer duration of follow-up are reqired to confirm these findings in our country Issued also as CD Azathioprine Neuromyelitis Rituximab Ahmed Nemr , Supervisor Nevin Moheildin , Supervisor Sherif Hamdy , Supervisor http://172.23.153.220/th.pdf Amira Cataloger Nazla Revisor ddc TH 82978 82978 ddc 0 CUCL cl210 2024-02-11 Cai01.11.20.Ph.D.2021.Mo.R 01010110084648000 2023-09-22 00:00:00 TH ddc 0 CUCL cl2u8 2024-02-11 Cai01.11.20.Ph.D.2021.Mo.R 01020110084648000 2023-09-22 00:00:00 84648.CD CD